Pulmonary Hypertension Due to Left Heart Disease
7
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.
Pulmonary Hypertension Biorepository and Registry
A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)
Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension
Telemonitoring to Treat Group 2 Pulmonary Hypertension
Training in HFpEF-PH
Registry for Pulmonary Hypertension Due to Left Heart Disease in China